Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GRM8 | O00222 | 1/20 | 0.37 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.37 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11797090 | 0.74 | PTPN1 (0.35) | PTPN1 | |
| SCHEMBL31410914 | 0.74 | PTPN1 (0.35) | PTPN1 | |
| Methane SCHEMBL28757480 | 0.73 | PTPN1 (0.34) | PTPN1 | |
| SCHEMBL14879850 | 0.72 | SMN1; SMN2 (0.37) | SMN1; SMN2POLB | |
| SCHEMBL3262814 | 0.72 | CYP3A4 (0.40) | CYP2C19ALOX15TDP1PTPN1PTPN2 | |
| SCHEMBL1427712 | 0.72 | CYP3A4 (0.40) | CYP2C19ALOX15TDP1PTPN1PTPN2 | |
| SCHEMBL30879479 | 0.72 | CYP3A4 (0.40) | CYP2C19ALOX15TDP1PTPN1PTPN2 | |
| SCHEMBL8994736 | 0.72 | CYP3A4 (0.40) | CYP2C19ALOX15TDP1PTPN1PTPN2 | |
| SCHEMBL7583136 | 0.72 | PTPN1 (0.36) | CYP2C19TSHRPTPN1 | |
| SCHEMBL22504293 | 0.72 | PTPN1 (0.36) | CYP2C19TSHRPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10272081-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2019-04-30 | — | — | US | disclosed |
| US-20180360828-A9 | SHIP1 MODULATORS AND METHODS RELATED THERETO | NEOLEUKIN THERAPEUTICS, INC. | 2018-12-20 | — | — | US | disclosed |
| US-20180161324-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2018-06-14 | — | — | US | disclosed |
| US-9937167-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2018-04-10 | — | — | US | disclosed |
| US-20170224682-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | NEOLEUKIN THERAPEUTICS, INC. | 2017-08-10 | — | — | US | disclosed |
| US-9540353-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS (CANADA) INC. (CA) | 2017-01-10 | — | — | US | disclosed |
| US-20160257671-A2 | SHIP1 MODULATORS AND METHODS RELATED THERETO | NEOLEUKIN THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20150336935-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2015-11-26 | — | — | US | disclosed |
| EP-2943470-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | Aquinox Pharmaceuticals (Canada) Inc. (CA) | 2015-11-18 | — | — | EP | disclosed |
| WO-2014110036-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2014-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10272081-B2 | SHIP1 modulators and methods related thereto | PPP1R1B, PPM1A, PPM1D | APLNR 1790/4885SMN1; SMN2 804/4885POLB 3330/4885 |
| US-20150336935-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPM1A, PPM1D, PPP1R1B | APLNR 2055/4885SMN1; SMN2 878/4885POLB 3360/4885 |
| US-20180360828-A9 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPP1R1B, PPM1A, PPM1D | APLNR 1790/4885SMN1; SMN2 804/4885POLB 3330/4885 |
| US-20170224682-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPP1R1B, PPM1A, PPM1D | APLNR 1790/4885SMN1; SMN2 804/4885POLB 3330/4885 |
| US-20160257671-A2 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPP1R1B, PPM1A, PPM1D | APLNR 1790/4885SMN1; SMN2 804/4885POLB 3330/4885 |
| US-20180161324-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPP1R1B, PPM1A, PPM1D | APLNR 1790/4885SMN1; SMN2 804/4885POLB 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.